Dr Reddy's settles patent row with Vivus; stock gains over 7%

The stock opened at Rs 2,130 and had hit a high and low of Rs 2,169 and Rs 2,121 respectively

Shares of Dr Reddy's Laboratories gained as much as 7.3% to Rs 2,169 in an otherwise range-bound market after Nasdaq-listed Vivus on Thursday entered into a settlement agreement with Dr Reddy’s to resolve a long-pending patent litigation related to weight management capsule Qsymia.

According to a statement issued by the US-based drug maker, the litigation, pending since 2015, resulted from the submission of an abbreviated new drug application (Anda) by Dr Reddy’s seeking approval to market generic versions of Qsymia.

The settlement permits the Hyderabad-based drugmaker to begin selling a generic version of Qsymia from June 2025, or earlier under certain circumstances.